Frank Anthony Lattuca is a pharmacist who is specialized in Oncology in Rochester, New York. Patients can reach him at 601 Elmwood Ave, Rochester or contact him on 585-509-4824. Active license number of Frank Anthony Lattuca is 064719 for Oncology in New York. Frank Anthony Lattuca is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Frank Anthony Lattuca speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Frank Anthony Lattuca
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Male
Location:
601 Elmwood Ave, Rochester, New York, 14642-0001
Phone:
585-509-4824
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Frank Anthony Lattuca are as mentioned below.
NPI Number:
1487277588
NPI Enumeration Date:
22 May, 2020
NPI Last Update On:
22 May, 2020
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Frank Anthony Lattuca are as mentioned below.
Specialization
License Number
State
Status
Oncology
064719
New York
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
87 Twin Oak Dr, Rochester, New York
Zip:
14606-4413
Phone Number:
--
Fax Number:
--
Patients can reach Frank Anthony Lattuca at 601 Elmwood Ave, Rochester, New York or can call on phone at 585-509-4824.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.